Royalty Report: Diagnostic, Drugs, Disease – Collection: 4047


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Diagnostic
  • Drugs
  • Disease
  • Pharmaceuticals
  • HIV / AIDs
  • Device
  • Diagnostic Substances
  • Medical

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 4047

License Grant
The Company announced a development Agreement with the Licensee, for the development of a new multiplex product that would be developed on DPP®, Dual Path Platform, and which would be marketed exclusively by the Licensee under an exclusive limited DPP® License.

The Agreement with the Licensee contemplated that the Company would enter into a License Agreement subject to the satisfaction of certain development and other conditions.  

On January 19, 2009, the Licensor granted, effective December 31, 2008, a limited exclusive License within a defined field of application for the Licensor's DPP® technology to the Licensee.

License Property
The Company’s main products are three rapid tests for the detection of HIV antibodies in whole blood, serum and plasma samples, two of which were approved by the FDA in 2006; the third is sold for export only. All of the Company’s products that are currently being developed are based on its patented Dual Path Platform (DPP®), which is a unique diagnostic point-of-care platform that has certain advantages over lateral flow technology. The Dual Path Platform (DPP®) POC technology was awarded United States Patent No. 7,189,522 in March 2007.

IPSCIO Record ID: 4046

License Grant
The Company signed an Agreement with the Brazilian Licensee for the transfer of technology for patents applied in Brazil or other Mercosur countries for the term of the patents and the transfer of all technical information related to DPP® HIV 1/2 rapid test and the process to obtain rapid test for the detection of HIV1/2 by the DPP® technology.
License Property
This Agreement contemplates the scientific and technological co-operation between the Company and the Licensee for such activities so that the Licensee will be able to manufacture the DPP® technology in Brazil.  Under the Agreement, after the Product registration by Brazil’s National Health Surveillance Agency, the Company will supply product and the Licensee will do their best efforts to purchase each year for a period of three years from the Company the amount of 833,333 units of product at a product transfer price of $3.00 per unit for a minimum aggregate purchase obligation equal to $7.5M.  Following the purchase of $7.5 million, during each of the succeeding two years, Licensee will purchase test components as specified by Licensee at an aggregate purchase price of $1.25 million in each of the fourth and fifth year.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 7270

License Grant
Licensor hereby grants to Licensee and Licensee hereby accepts from Licensor an exclusive worldwide license during the Term under the Licensor's Lateral Flow Patents to manufacture the HIV Barrel Product solely for sale to Inverness.
License Property
Licensor, among other activities, is in the business of developing, marketing and selling products used to diagnose various diseases, including HIV, and owns or has the right to grant licenses to a number of patents pertaining to HIV diagnosis, including the Inverness Lateral Flow Patents. Licensor asserts that the HIV Barrel Product is within the scope of the claims of the Licensor's Lateral Flow Patents.

HIV Barrel Product means the product for HIV testing known as SURE CHECK(R) HIV 1/2 as described in Licensee's PMA on file with the FDA and further described in the SURE CHECK(R) HIV 1/2 package insert, Catalog #HIV202, together with any improvements thereto.

HIV Cassette Product means the Licensee's product currently known as HIV 1/2 STAT PAK(TM) as described in Licensee's PMA on file with the FDA and further described in the HIV 1/2 STAT PAK(TM) package insert, Catalog #HIV 102, which is the subject of a Related Document.

Our main products presently commercially available are three rapid tests for the detection of HIV antibodies in whole blood, serum and plasma samples, two of which were approved by the FDA last year. These products employ single path lateral flow technology.  Lateral flow, whether single or dual path, generally refers to the process of a sample flowing from the point of application on a test strip to provide a test result on a portion of a strip downstream from either the point of application of the sample or of another reagent.

Field of Use
Barrel Field means diagnostic testing for the presence of HIV antibodies utilizing an integrated in-vitro diagnostic testing device that (i) is a single use disposable device (ii) collects a physiologic sample from a patient directly into the device and delivers that sample into a system contained in the device  where the reaction reagent medium (for example, a reagent strip) is enclosed in a barrel or other container with a transparent portion which allows the results of the reaction to be visible, designed to protect the user from contact with its contents, (iii) produces a visually readable result in less than 20 minutes, and (iv) is primarily designed to be used in a Point of Care environment or for self-testing by consumers.

IPSCIO Record ID: 28793

License Grant
The present Contract for the Transfer of Technology and Material calls for the scientific and technological co-operation between the Brazilian Licensee and the Licensor, for the production of the HIV ½ Stat-Pak.
License Property
The Licensor is a company having as its main purpose the production of lateral flow rapid diagnostic test kits including but not limited to Rapid test kit for HIV – HIV ½ Stat-Pak.

HIV 1/2 STAT-PAK® assay is a single use, immunochromatographic test used to detect antibodies to Human Immunodeficiency Virus Type 1 (HIV-1) and Type 2 (HIV-2) in fingerstick whole blood, venous whole blood, serum and plasma specimens.

Field of Use
Rapid test kit for HIV ½ produced by the Licensee termed HIV ½Stat – Pak composed of tests based on immunochromatography and lateral low, adapted to rapid supports for use with serum, plasma or whole blood, sealed in individual laminated foil pouches containing also, lancets, transfer loops, band-aids and dessicants.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.